170 related articles for article (PubMed ID: 26202593)
1. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.
Estes C; Abdel-Kareem M; Abdel-Razek W; Abdel-Sameea E; Abuzeid M; Gomaa A; Osman W; Razavi H; Zaghla H; Waked I
Aliment Pharmacol Ther; 2015 Sep; 42(6):696-706. PubMed ID: 26202593
[TBL] [Abstract][Full Text] [Related]
2. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
Örmeci N; Malhan S; Balık İ; Ergör G; Razavi H; Robbins S
Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
4. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.
McDonald SA; Azzeri A; Shabaruddin FH; Dahlui M; Tan SS; Kamarulzaman A; Mohamed R
Appl Health Econ Health Policy; 2018 Dec; 16(6):847-857. PubMed ID: 30145775
[TBL] [Abstract][Full Text] [Related]
5. Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.
McDonald SA; Dahlui M; Mohamed R; Naning H; Shabaruddin FH; Kamarulzaman A
PLoS One; 2015; 10(6):e0128091. PubMed ID: 26042425
[TBL] [Abstract][Full Text] [Related]
6. Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost-effectiveness model.
Ezzat S; Gamkrelidze I; Osman A; Gomaa A; Roushdy A; Esmat G; Razavi H; Blach S; Abdel-Razek W; El-Akel W; Waked I
Liver Int; 2023 Jul; 43(7):1417-1426. PubMed ID: 37073160
[TBL] [Abstract][Full Text] [Related]
7. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
[TBL] [Abstract][Full Text] [Related]
8. The Burden of Obesity in Egypt.
Aboulghate M; Elaghoury A; Elebrashy I; Elkafrawy N; Elshishiney G; Abul-Magd E; Bassiouny E; Toaima D; Elezbawy B; Fasseeh A; Abaza S; Vokó Z
Front Public Health; 2021; 9():718978. PubMed ID: 34513789
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
10. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C infection in Egypt: prevalence, impact and management strategies.
Gomaa A; Allam N; Elsharkawy A; El Kassas M; Waked I
Hepat Med; 2017; 9():17-25. PubMed ID: 28553150
[TBL] [Abstract][Full Text] [Related]
12. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.
Mennini FS; Marcellusi A; Andreoni M; Gasbarrini A; Salomone S; Craxì A
Clinicoecon Outcomes Res; 2014; 6():303-10. PubMed ID: 24971024
[TBL] [Abstract][Full Text] [Related]
13. Economic cost and burden of dengue during epidemics and non-epidemic years in Taiwan.
Luh DL; Liu CC; Luo YR; Chen SC
J Infect Public Health; 2018; 11(2):215-223. PubMed ID: 28757293
[TBL] [Abstract][Full Text] [Related]
14. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the burden of diabetes in Poland].
Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
[TBL] [Abstract][Full Text] [Related]
16. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
17. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.
Meijerink H; White RA; Løvlie A; de Blasio BF; Dalgard O; Amundsen EJ; Melum E; Kløvstad H
BMC Infect Dis; 2017 Aug; 17(1):541. PubMed ID: 28774261
[TBL] [Abstract][Full Text] [Related]
18. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
19. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality.
Lehman EM; Wilson ML
J Viral Hepat; 2009 Sep; 16(9):650-8. PubMed ID: 19413698
[TBL] [Abstract][Full Text] [Related]
20. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
